Noradrenalin Aguettant (Noradrenaline Tartrate)

Noradrenaline tartrate, the active ingredient in Noradrenalin Aguettant, is a sympathomimetic presented as a sterile intravenous solution approved in the European Union. It acts as a potent vasopressor to rapidly increase systemic vascular resistance and raise arterial pressure in patients with acute hypotension, septic shock, or cardiac arrest.

GNH USA supplies Noradrenalin Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, intensive care units and emergency departments worldwide, ensuring consistent quality, regulatory compliance, and reliable cold‑chain logistics where required.

Noradrenalin Aguettant is a vasopressor used in critical care to manage severe circulatory failure.

- Hypotension: restores arterial pressure by inducing vasoconstriction in patients with acute low blood pressure. - Septic shock: supports hemodynamics by increasing systemic vascular resistance in sepsis‑related circulatory collapse. - Cardiac arrest: provides immediate pressor support during resuscitation to improve coronary and cerebral perfusion.

Noradrenalin Aguettant may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache occurring during infusion. - Tachycardia: increased heart rate due to β‑adrenergic stimulation. - Peripheral ischemia: reduced blood flow causing cold extremities. - Nausea: transient nausea reported in some patients. - Hypertension: excessive rise in blood pressure if dose is high.

Serious or Rare Side Effects: - Cardiac arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: reduced coronary perfusion leading to chest pain or infarction. - Tissue necrosis: severe local vasoconstriction causing skin or limb damage. - Pulmonary edema: fluid accumulation in lungs due to high afterload. - Severe hypertension: dangerous spikes in arterial pressure requiring immediate intervention.

When using Noradrenalin Aguettant, clinicians should observe specific precautions to minimize risks. - Dose titration: adjust infusion rate to achieve target blood pressure while monitoring hemodynamics. - Cardiac monitoring: continuous ECG and heart rate observation for arrhythmias. - Peripheral perfusion: assess limb circulation regularly to detect ischemia. - Fluid balance: ensure adequate intravascular volume before initiating therapy. - Contraindications: avoid use in patients with known hypersensitivity to noradrenaline or catecholamines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Noradrenalin Aguettant can interact with other agents, altering its pressor effect or safety profile.

Major Interactions (Avoid): - β‑blockers: may blunt the β‑adrenergic component, reducing heart rate response. - MAO inhibitors: increase risk of hypertensive crisis when combined. - Vasodilators: concurrent use can counteract pressor effect, requiring higher doses.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: may enhance vasoconstriction and raise blood pressure. - Tricyclic antidepressants: additive sympathomimetic activity may cause excessive hypertension. - Diuretics: can exacerbate hypovolemia, intensifying vasopressor requirements.